Navigation Links
ADA releases updated position paper on vegetarian diets
Date:7/1/2009

CHICAGO The American Dietetic Association has released an updated position paper on vegetarian diets that concludes such diets, if well-planned, are healthful and nutritious for adults, infants, children and adolescents and can help prevent and treat chronic diseases including heart disease, cancer, obesity and diabetes.

ADA's position, published in the July issue of the Journal of the American Dietetic Association, represents the Association's official stance on vegetarian diets:

"It is the position of the American Dietetic Association that appropriately planned vegetarian diets, including total vegetarian or vegan diets, are healthful, nutritionally adequate and may provide health benefits in the prevention and treatment of certain diseases. Well-planned vegetarian diets are appropriate for individuals during all stages of the life-cycle including pregnancy, lactation, infancy, childhood and adolescence and for athletes."

ADA's position and accompanying paper were written by Winston Craig, PhD, MPH, RD, professor and chair of the department of nutrition and wellness at Andrews University; and Reed Mangels, PhD, RD, nutrition advisor at the Vegetarian Resource Group, Baltimore, Md.

The revised position paper incorporates new topics and additional information on key nutrients for vegetarians, vegetarian diets in the life cycle and the use of vegetarian diets in prevention and treatment of chronic diseases. "Vegetarian diets are appropriate for all stages of the life cycle," according to ADA's position. "There are many reasons for the rising interest in vegetarian diets. The number of vegetarians in the United States is expected to increase over the next decade."

Vegetarian diets are often associated with health advantages including lower blood cholesterol levels, lower risk of heart disease, lower blood pressure levels and lower risk of hypertension and type 2 diabetes, according to ADA's position. "Vegetarians te
'/>"/>

Contact: Jennifer STarkey
media@eatright.org
312-899-4802
American Dietetic Association
Source:Eurekalert

Page: 1 2

Related biology news :

1. Afghanistan releases its first-ever list of protected species
2. DOE JGI releases expanded version of Phytozome.net
3. ADA releases updated position statement on functional foods
4. Complete Genomics releases proof-of-concept data for its sequencing technology for the first time
5. The International Society for Stem Cell Research releases new guidelines
6. American Dietetic Association releases 2008 nutrition trends survey
7. SNM releases new fact sheet on breast cancer and molecular imaging
8. Neurotechnology Releases SentiSight 2.0 SDK Universal Object Recognition Technology
9. Neurotechnology Releases SentiSight 2.0 SDK Universal Object Recognition Technology
10. EPA releases report on climate change and health
11. EPA releases science assessment on health effects of nitrogen oxides
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2015)... GOTHENBURG, Sweden , July 21, 2015 ... sensor FPC1025. Already received as well as expected revenues in 2015 ... included in FPC,s communicated revenue guidance of approximately 2,200 MSEK for ... is a leading smartphone manufacturer in China ... selected FPC1 02 5 for Axon ...
(Date:7/20/2015)... 20, 2015  Acuity Market Intelligence,s latest research ... of Commerce and Privacy" forecasts that between 2014 ... will be downloaded to smart mobile devices by ... market is projected to generate more than $67.9 ... seven-year forecast period.    "Biometrics is ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the fourth quarter ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... out of the George Washington University (GW), published in ... Sciences ( PNAS ), reveals another piece of ... behavioral diseases such as autism. Anthony-Samuel LaMantia, Ph.D., professor ... Medicine and Health Sciences (SMHS) and director of the ...
... press credentials for the American Chemical Society,s 245th National Meeting ... New Year will be held April 7-11, 2013, in New ... and others expected to gather in the Crescent City for ... from astronomy to zoology ― the meeting will offer ...
... keep their cellular calcium concentration at a very low ... many critical cellular functions (an elevated calcium concentration over ... mechanisms ensure that calcium concentration quickly returns to its ... of cellular calcium regulation underlie almost all neurodegenerative diseases. ...
Cached Biology News:GW professor discovers new information in the understanding of autism and genetics 2Press registration opens for 2013 meeting of world's largest scientific society 2
(Date:7/29/2015)... July 29, 2015  AmnioChor Inc., an early stage ... very pleased to announce that the Musculoskeletal Transplant Foundation ... to invest in their seed round of development of ... storage capabilities. AmnioChor,s technology allows cryopreservation ... human stem cells living within those tissues. Amnion is ...
(Date:7/29/2015)... DIEGO , July 29, 2015  Pfenex Inc. ... 2015 financial results will be released on Thursday, August ... am Eastern Time, Pfenex management will host a conference ... business update.  A press release outlining the financial results ... the call. Please call 1-866-376-8058 (US) or ...
(Date:7/29/2015)... ... July 29, 2015 , ... The third Medical Innovation Impact Index (MI3) ... in particular, drug/device combinations. The current system received a score of 0 (range -10 ... Centered Innovation (iPCI) of Fairleigh Dickinson University’s ( FDU ) Rothman Institute of ...
(Date:7/29/2015)... QUEBEC CITY , July 29, 2015 /PRNewswire/ ... (the "Company") today announced it has selected an optimized ... important milestone in the development of a new ... The MAPK pathway represents a prime target for ... significant antitumor activities and survival benefits for B-Raf ...
Breaking Biology Technology:The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... ... announced results from the RE-COVER(TM) study investigating dabigatran etexilate (150 mg ... patients with acute VTE. Results of the trial were presented ... published online in the New England Journal of Medicine .(1) ...
... , NEW YORK, Dec. 4 ... of its IL-3R targeting agents, SL-401 and SL-501, in both ... (CML) have been selected for poster presentation at the upcoming 51st ... held in New Orleans from December 5-8, 2009. The poster will ...
... , DALLAS, Dec. 3 ... Board: ACCP), today provided an update on its European commercial ... a debilitating side effect of radiation treatment and chemotherapy. MuGard ... countries, including the UK, Germany, Italy, Norway, Greece and Sweden. ...
Cached Biology Technology:RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4
...
...
RatTRAPTM Assay is a solid-phase immunofixed enzyme activity assay for the determination of osteoclast-derived TRACP 5b activity in rat serum....
Applications include ELISA, immunochemistry, and Western blotting. Working Concentrations: ELISA: 0.005-0.05 U/ml, immunohisto/cytochemistry: 0.25-0.5 U/ml, Western blot: 0.1-0.25 U/ml....
Biology Products: